Virology News
43.5K views | +11 today
Follow
Virology News
Topical news snippets about viruses that affect people.  And other things. Like zombies B-)
Curated by Ed Rybicki
Your new post is loading...
Your new post is loading...
Scooped by Ed Rybicki
Scoop.it!

Scientists Report Headway In Hunt For Dengue Vaccine

Scientists Report Headway In Hunt For Dengue Vaccine | Virology News | Scoop.it
It's called "breakbone fever" because that's how bad you feel when you get it. There's no cure. But scientists have found powerful antibodies that could lead to the development of a simple vaccine.
more...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Ebola virus tricks the body and strips victims of dignity

Ebola virus tricks the body and strips victims of dignity | Virology News | Scoop.it
The Ebola virus plays two devastating tricks on the human body. It first disarms the immune defences which are meant to protect against an invading virus.
more...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Fewer Ebola Cases Go Unreported Than Thought, Study Finds

Fewer Ebola Cases Go Unreported Than Thought, Study Finds | Virology News | Scoop.it
Transmission of the Ebola virus occurs mostly within families, in hospitals and at funerals, not randomly like the flu, Yale scientists said.
more...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

FDA approves Gardasil 9 for prevention of cancers caused by five additional types of HPV

FDA approves Gardasil 9 for prevention of cancers caused by five additional types of HPV | Virology News | Scoop.it
The U.S. Food and Drug Administration today approved Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) for the prevention of certain diseases caused by nine types of Human Papillomavirus (HPV). Covering nine HPV types, five more HPV types than Gardasil (previously approved by the FDA), Gardasil 9 has the potential to prevent approximately 90 percent of cervical, vulvar, vaginal and anal cancers.

 

Thanks to Russell Kightley Media for the cervical cancer graphic

more...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Hybrid Delivery System Boosts DNA Vaccines Potential

Hybrid Delivery System Boosts DNA Vaccines Potential | Virology News | Scoop.it

Scientists from the University at Buffalo have created a novel hybrid system designed to deliver genetic antigens and elicit a strong immune response in patients, something DNA vaccines have so far failed to deliver. The hybrid, presented in the Proceedings of the National Academy of Science and described as a “hybrid biosynthetic gene therapy vector development and dual engineering capacity,” brings together two usually distinct technologies to create a hybrid vector: combining a bacterial cell and a synthetic polymer. The result was an immune response greater than both the individual technologies were able to produce in mouse models because of the new technology’s ability to deliver the DNA to antigen-presenting cells.

 
more...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Nature makes all articles free to view

Nature makes all articles free to view | Virology News | Scoop.it
Publisher permits subscribers and media to share read-only versions of its papers.
Ed Rybicki's insight:

Score 1 for the Open brigade!

more...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

US Ebola vaccine trial reports positive results

US Ebola vaccine trial reports positive results | Virology News | Scoop.it
A related vaccine is due to be tested in West Africa in 2015.

An experimental vaccine against Ebola virus seems to be safe and commands a strong immune response against the virus, according to tests in 20 healthy people in the United States. The results of the phase 1 trial are published in the New England Journal of Medicine1.

“All in all, I would say it was a successful phase 1 study,” says Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases (NIAID) in Bethesda, Maryland, which co-developed the drug with the London-based drug company GlaxoSmithKline (GSK). “The next steps are to move ahead with a larger efficacy trial in West Africa.”

 

The vaccine is similar to one that is on track to be tested in larger trials in West Africa, which are likely begin early next year. In these phase 2 and phase 3 trials, thousands of people who are at risk of contracting the virus, such as health workers, will receive the vaccine to determine whether it can protect against infection.

more...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

A Top Ten list for economically important plant viruses

A Top Ten list for economically important plant viruses | Virology News | Scoop.it

The concept of “Top Ten” lists of plant pathogens is in vogue in recent years, and plant viruses are no exception. However, the only list available has more to do with historical and scientific worth than it has to do with economic impact on humans and their animals. This review will discuss the most important plant viruses that cause serious harm to food plants that sustain the bulk of humankind.

 
Ed Rybicki's insight:

I offered it to them over at Molecular Plant Pathology; I did...B-)

more...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Genetically engineered 'plantibodies' to halt Ebola

Genetically engineered 'plantibodies' to halt Ebola | Virology News | Scoop.it

While little can be done to curb the current outbreak of Ebola in Africa, when the next outbreak happens, the world will be armed with cheap but powerful biologics made using plants, says UCT plant biotechnologist Professor Ed Rybicki.


Recent news from the BBC is the World Health Organisation reporting that a serum made from the blood of Ebola survivors could be made available in Liberia within weeks.

Liberia has been hardest hit by Ebola deaths, followed by Guinea and Sierra Leone, and the US Centres for Disease Control and Prevention estimates that cases in Liberia and Sierra Leone will rise dramatically by January 2015.

The WHO's Dr Marie-Paule Kieny says trials for two promising vaccines could produce initial results by the end of the year.

Worldwide, governments have been on high alert to halt the spread of the disease, spotlighting the need for emergency vaccine technology: vaccines that can be made quickly, cheaply and safely.

And biologics - drugs that can be created by genetically re-engineering plants, or even plant viruses, to produce vaccines and antibodies needed to curb diseases such as Ebolavirus - could be the answer.

Biologics are not new, says Rybicki, a genetic engineer who heads up UCT's Biopharming Research Unit (BRU), but they are the latest growth area for pharmaceutical companies, and part of new approaches to disease prevention.

 

Ebola graphic from Russell Kightley Media

more...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Infographic: This is the future of vaccine technology

Infographic: This is the future of vaccine technology | Virology News | Scoop.it
more...
Scooped by Ed Rybicki
Scoop.it!

Merck enters the Ebola Vaccine Race

Merck enters the Ebola Vaccine Race | Virology News | Scoop.it

Merck has struck a agreement with NewLink Genetics to licence their investigationalEbola vaccine, rVSV-EBOV. The $50 million agreement gives Merck exclusive rights to develop, manufacture, and distribute the vaccine across the world.

This partnership should allow NewLink to keep pace with the huge effort by GlaxoSmithKline and the National Institute of Allergy and Infectious Diseases (NIAID) to developer their Ebola vaccine candidate.

Ed Rybicki's insight:

FINALLY, Big Pharma starts to jostle for position with Ebola vaccines. FINALLY!

more...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Vaccines Work. Here Are the Facts.

Vaccines Work. Here Are the Facts. - The Nib - Medium
The risks, the misinformation, and the science behind history’s greatest life saver
Ed Rybicki's insight:

Any questions??

more...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

A biosensor to peer into insides of HIV-infected cell

A biosensor to peer into insides of HIV-infected cell | Virology News | Scoop.it
A new biosensor can measure what is going on within HIV-infected cells in real-time and also provide insight on the interactions between the AIDS virus and the tuberculosis causing bacteria within the cells.
more...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Ebola’s Mystery: One Boy Lives, Another Dies

Ebola’s Mystery: One Boy Lives, Another Dies | Virology News | Scoop.it
Over and over, doctors have been confounded by the divergent paths of Ebola patients whose cases appeared similar at first.
more...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

HIV Handbook: facts, figures, and vaccines

HIV Handbook: facts, figures, and vaccines | Virology News | Scoop.it

The 1st of December marked World AIDS Day 2014, and saw millions of people from across the world pledging support for the eradication of HIV and the proper treatment of AIDS patients. Eradication remains the ultimate goal, and vaccines are almost certainly the tool for the job. But researchers have for decades struggled to tame a virus with so many defence mechanisms. With high profile disappointments, such as the Thai Trial, confidence waned in HIV vaccine candidates. But slowly different parts of the virus are being cracked by teams across the globe, and the Thai Trial’s ALVAC and AIDSVAX combo may even be making a comeback.

 
more...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Updated – Viruses Resources on Ebola Virus and other Filoviruses

Updated – Viruses Resources on Ebola Virus and other Filoviruses | Virology News | Scoop.it
Updated on 28 November 2014   

Given the current dramatic evolution of the Ebola virus disease outbreak in West Africa, Dr. Jens H. Kuhn from the NIH/NIAID/IRF-Frederick has kindly compiled the following list of resources related to the Ebola virus and other filoviruses that were published in the journal Virusesand are hence openly available. We will update the list as new papers on the subject are published.

 

Ed Rybicki's insight:

What a useful resource!

more...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Slowdown in new Ebola cases offers a chance for control efforts to get ahead of the epidemic

An apparent slowdown in new cases of Ebola disease in Liberia and Guinea should be taken advantage of. Almost one year after an Ebola epidemic began in West Africa there are at last encouraging signs that it may be receding in some regions. But those responding to the epidemic must not drop their guard — rather, they should seize upon the chance to finish the job.

 
more...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Why Southern Africa may be the best place on Earth for health science research

Why Southern Africa may be the best place on Earth for health science research | Virology News | Scoop.it
Genetic advantage: why Southern Africa may be the best place on Earth for health science research
more...
No comment yet.
Scooped by Ed Rybicki
Scoop.it!

FDA Grants Fast Track Designation to RSV F-Protein Nanoparticle Vaccine

FDA Grants Fast Track Designation to RSV F-Protein Nanoparticle Vaccine | Virology News | Scoop.it
Novavax, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Novavax’ RSV F-Protein nanoparticle vaccine candidate (RSV F vaccine) for protection of infants via maternal immunization.
more...
No comment yet.